Non-peptide small-molecule inhibitors designed to target the MDM2-p53 interaction may have a great therapeutic potential for the treatment of many types of human cancer with wild-type p53. Using a powerful structure-based strategy, we have now designed a class of highly potent, non-peptide, drug-like, small- molecule inhibitors of the MDM2-p53 interaction. Based upon our promising preliminary results, we propose to further optimize this class of inhibitors, to evaluate their therapeutic potential in vitro and in vivo, and to elucidate their mechanisms of action in vitro and and in vivo. Our long-term goal in this project is to develop potent and specific non-peptide small-molecule inhibitors of the MDM2-p53 interaction for the treatment of human cancer. To achieve our goal, we will pursue the following Specific Aims:
Aim 1 : (a).Performance of computational structure-based design of new inhibitors to further optimize this class of promising compounds; (b).Determination of high resolution three-dimensional structures of potent inhibitors complexed with MDM2 protein through x-ray crystallography.
Aim 2 : Chemical synthesis of inhibitors designed in Aim 1 and biotin-labeled compounds.
Aim 3 : Determination of their binding and specificity to MDM2 protein using complementary fluorescence- polarization-based and NMR-based methods.
Aim 4 : Evaluation of their cellular activity and specificity in human cancer cells with wild-type, or mutated or deleted p53 status and selectivity over normal cells, and elucidation of their cellular mechanisms of action.
Aim 5 : Determination of the therapeutic potential of several of the most promising MDM2 inhibitors in animal models of human cancer and elucidation of their in vivo mechanisms of action. With these tasks successfully completed, we will be able to bring a class of highly potent and optimizednon- peptide small-molecule inhibitors of the MDM2-p53 interaction into advanced preclinical development. It is predicted that such potent and specific small-molecule inhibitor of the MDM2-p53 interaction will be effective for the treatment of many types of human cancer with wild-type p53 status.
|Aguilar, Angelo; Lu, Jianfeng; Liu, Liu et al. (2017) Discovery of 4-((3'R,4'S,5'R)-6?-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2?-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3?-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minut J Med Chem 60:2819-2839|
|Lu, Jianfeng; McEachern, Donna; Li, Shunqiang et al. (2016) Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. Mol Cancer Ther 15:2887-2893|
|Hoffman-Luca, C Gianna; Ziazadeh, Daniel; McEachern, Donna et al. (2015) Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. Clin Cancer Res 21:2558-68|
|Hoffman-Luca, C Gianna; Yang, Chao-Yie; Lu, Jianfeng et al. (2015) Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. PLoS One 10:e0128807|
|Wang, Shaomeng; Sun, Wei; Zhao, Yujun et al. (2014) SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res 74:5855-65|
|Aguilar, Angelo; Sun, Wei; Liu, Liu et al. (2014) Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. J Med Chem 57:10486-98|
|Zhao, Yujun; Liu, Liu; Sun, Wei et al. (2013) Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc 135:7223-34|
|Zhao, Yujun; Yu, Shanghai; Sun, Wei et al. (2013) A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 56:5553-61|
|Verhaegen, M; Checinska, A; Riblett, M B et al. (2012) E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 31:828-41|
|Azmi, A S; Philip, P A; Beck, F W J et al. (2011) MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene 30:117-26|
Showing the most recent 10 out of 16 publications